Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.

被引：0
|
作者：
Liu, Yue
Ding, Kefeng
Xiao, Qian
He, Jinjie
Hu, Hanguang
Du, Jinlin
Zhu, Yuping
Chen, Jiaqi
Liu, Zhuo
Wang, Jianping
Sun, Lifeng
Xu, Dong
Li, Jun
Liao, Xiujun
Wang, Jianwei
Cai, Yibo
Cai, Cheng
Jin, Zhekang
Yuan, Ying
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Dept Colorectal Surg & Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Univ, Colorectal Surg, Jinhua Hosp, Jinhua, Zhejiang, Peoples R China
[5] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Colorectal Surg, Hangzhou, Zhejiang, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 2, Colorectal Surg & Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-3532-2370-7650-2700; 283-237-255; 281-206-4957-3975-3408-6824; 261-492-12161; 261-492-2769; 613-135-244-3829; 281-318-430; 5; 4; 2; 2414; 1589; 92; 239; 6; 3; 1; 38116-38094-8; 38092-34311; 38092-29234; 38092-18849;
D O I：
10.1200/JCO.2024.42.3_suppl.131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [1] Updated results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.
    Ding, Ke-Feng
    Liu, Yue
    Xiao, Qian
    He, Jinjie
    Hu, Hanguang
    Du, Jinlin
    Zhu, Yuping
    Chen, Jiaqi
    Liu, Zhuo
    Wang, Jianping
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Liao, Xiujun
    Wang, Jianwei
    Cai, Yibo
    Cai, Cheng
    Jin, Zhekang
    Yuan, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 138 - 138
  • [2] Updated results of ALTER-C002: Anlotinib combined with CAPEOX in first-line treatment of patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer.
    Ding, Ke-Feng
    Liu, Yue
    Du, Jinlin
    Zhu, Yuping
    Liu, Zhuo
    Wang, Jianping
    Xu, Dong
    Li, Jun
    Liao, Xiujun
    Sun, Lifeng
    He, Jinjie
    Xiao, Qian
    Wang, Jianwei
    Cao, Hongfeng
    Cai, Yibo
    Cai, Cheng
    Jin, Zhekang
    Yuan, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] A single-arm, multicenter, phase II study of anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ALTER-C002)
    Ding, K.
    Liu, Y.
    Du, J.
    Zhu, Y.
    Xu, D.
    Li, J.
    Liao, X.
    He, J.
    Wang, J.
    Liu, Z.
    Sun, L.
    Xiao, Q.
    Wang, J.
    Cao, H.
    Cai, Y.
    Cai, C.
    Jin, Z.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S545 - S545
  • [4] Anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer: A single-arm, phase II study (ALTER-C-002 trial).
    Ding Ke-Feng
    Liu Yue
    Chen Jiaqi
    Sun Lifeng
    Xu Dong
    Liao Xiujun
    Xiao Qian
    Li Jun
    Yuan Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [5] Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial)
    Ding, K.
    Liu, Y.
    Chen, J.
    Ying, J.
    Xu, Q.
    Xu, D.
    Sun, L.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S440 - S440
  • [6] Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study
    Xu, Chang
    Ren, Jing
    Liu, Changqing
    Gai, Yi
    Cheng, Xiangyu
    Wang, Yusheng
    Wang, Guangyu
    ANTI-CANCER DRUGS, 2025, 36 (05) : 383 - 393
  • [7] A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
    He, Jinjie
    Liu, Yue
    Liu, Chengcheng
    Hu, Hanguang
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Wang, Junye
    Chen, Xiaobing
    Lin, Rongbo
    Jiang, Yi
    Zhang, Yanqiao
    Zhang, Weisheng
    Cheng, Ying
    Wu, Xiaohong
    Fang, Mingzhi
    Li, Enxiao
    Xu, Ye
    Chen, Ye
    Li, Jiayi
    Cui, Yanyan
    Pan, Zhanyu
    Zhang, Songnan
    Yuan, Ying
    Ding, Kefeng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [8] A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
    He, Jinjie
    Liu, Yue
    Liu, Chengcheng
    Hu, Hanguang
    Sun, Lifeng
    Xu, Dong
    Li, Jun
    Wang, Junye
    Chen, Xiaobing
    Lin, Rongbo
    Jiang, Yi
    Zhang, Yanqiao
    Zhang, Weisheng
    Cheng, Ying
    Wu, Xiaohong
    Fang, Mingzhi
    Li, Enxiao
    Xu, Ye
    Chen, Ye
    Li, Jiayi
    Cui, Yanyan
    Pan, Zhanyu
    Zhang, Songnan
    Yuan, Ying
    Ding, Kefeng
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
  • [9] A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer
    Ding, K.
    Liu, Y.
    Song, Y.
    Xu, D.
    Li, J.
    Wang, J.
    Chen, X.
    Lin, R.
    Jiang, Y.
    Zhang, Y.
    Zhang, W.
    Cheng, Y.
    Wu, X.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S736 - S736
  • [10] Updated survival results of BBCAPX-II: Sintilimab combined with bevacizumab and CapeOx as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer
    Yuan, Ying
    Zhu, Ning
    Fang, Xuefeng
    Zhong, Chenhan
    Li, Dan
    Wang, Liu-Hong
    Li, Jun
    Weng, Shanshan
    Hu, Hanguang
    Dong, Caixia
    Song, Yongmao
    Xu, Dong
    Wang, Jianwei
    Sun, Lifeng
    Wang, Jian
    Liao, Xiujun
    Yu, Ningjuan
    Zhang, Suzhan
    Ding, Ke-Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345